Clinical Trial

Zilucoplan for Severe gMG Exacerbations

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-10.
Status change: Not Yet Recruiting → Recruiting 2026-02-20
Trial Details
NCT Number NCT07215949
Lead Sponsor Miriam Freimer
Collaborators: UCB Pharma
Conditions Generalized Myasthenia Gravis (gMG)
Enrollment 15 participants
Start Date 2026-01-20
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-23